Marco Filipe Moedas, 

was born in Portugal in 1986 in the city of Almada, just across the river from Lisbon.
Graduated from Universidade Nova de Lisboa (FCT-UNL)  in Cellular and Molecular Biology in 2007 and followed by a M.Sc. from the Universidade de Lisboa (FCUL) in Human Molecular Biology in 2009. He joined Prof. Isabel Tavares de Almeida’s lab at Faculdade de Farmácia of the Universidade de Lisboa (FFUL) in 2010 as an analytical chemist in the area of IEM. Started his Ph.D. in 2011 with Prof. Margarida Silva at FFUL and with Prof. Ronald Wanders at the Amsterdam Academical Medical Center in the Netherlands (AMC, currently UMC) on the topic of xenobiotic metabolism, focusing on the effects of Sodium Valproate on liver metabolism.
In 2017 he rejoined Prof. Isabel Tavares de Almeida’s lab as analytical chemist until 2018 when he joined Prof. Anna Wredenberg’s lab at the Karolinska Institute in Stockholm Sweden as postdoctoral researcher. There he worked on establishing cellular, mouse and fruit fly models of mitochondrial disease, developing of new mass spectrometry-based methods for quantification of mitochondrial metabolites, and analysis of proteomes in human mitochondrial disease patients. Since 2022 he works as a clinical chemist at the national newborn screening laboratory at the Karolinska University Hospital (PKU-Lab) in Stockholm, in charge of maintenance and development of mass spectrometry-based methods and instruments related with newborn screening.